A Toronto-based research team is leading a five-year clinical trial to study liquid biopsies, a blood-based technology that detects traces of tumour DNA to improve cancer survivorship. The SHERLOCK project, led by Dr. Lillian Siu at the Princess Margaret Cancer Centre, aims to identify residual cancer cells in patients who have undergone curative treatments. Liquid biopsies offer a less invasive alternative to traditional imaging, enabling early detection of potential relapses. Participants like Paul Lonergan, who had tongue cancer, benefited from the technology by receiving targeted immunotherapy after tests revealed lingering tumour fragments. While promising, challenges remain, including false positives/negatives and high costs. Researchers emphasize the need for repeated testing and long-term studies to validate the technology's role in routine care. Despite these hurdles, the project could revolutionize cancer monitoring by detecting disease recurrence before clinical symptoms appear, offering patients better treatment options and reducing the need for aggressive interventions.

Mercy BioAnalytics has appointed Dr. Prasanth Reddy as Chief Medical Officer. His expertise in oncology will help enhance early cancer detection efforts.